Sign in
TerminatedNo phase

Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma

Key facts

Who runs it
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Where
Baltimore, United StatesSee the site
Trial code
Status
Terminated
People taking part
2 people enrolled
Started
17 Feb 2022
Ended
1 Apr 2024
Type of study
Interventional
Treatments tested
  • Combined Aerobic and Resistance Exercise Training
Record updated
4 April 2024
Why it stopped
Study terminated due to lack of funding

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Histologically confirmed diagnosis of RCC
  • Patients being treated with standard of Programmed cell death protein 1 (anti-PD-1) or anti-PD-L1 immune-checkpoint inhibitor-containing standard of care regimen including patients who are about to start treatment or have been on treatment for a maximum of 4 weeks prior to signing consent
  • Metastatic Measurable disease, as defined by RECIST 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 with a life expectancy ≥ six months
  • Physically able to enroll in the exercise program as determined by the treating medical oncologist and after review by Physical medicine and rehabilitation physicians at Johns Hopkins
  • Adequate bone marrow reserve and organ function measured within 28 days prior to administration of study treatment with the following key parameters:
  • Hematological:; Absolute neutrophil count ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L; Hemoglobin≥ 9.0 g/dL
  • Renal:; Serum Creatinine ≤ 1.5 x the upper limit of normal (ULN) or Calculated Creatinine clearance ≥ 30mL/min
  • Hepatic:; Total bilirubin ≤ 1.5 x ULN (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled); Serum Aspartate aminotransferase (AST) and serum Alanine aminotransferase (ALT) ≤ 2.5 x ULN (For patients with documented liver metastases AST and/or ALT ≤ 5 x ULN)

Who cannot take part

  • Known underlying uncontrolled brain metastatic lesions requires steroids therapy and/or radiotherapy
  • Major surgery within four weeks prior to enrollment
  • Radiotherapy for RCC 28 days prior to week 1 day 1
  • History of underlying cardiovascular, respiratory, musculoskeletal disease or joint problems that preclude moderate physical activity
  • The presence of bone metastasis in the spine, pelvis, and lower limbs
  • Currently physically active or moderately active as determined by Leisure Score Index of Godin Leisure-Time Exercise Questionnaire (GSLTPAQ)

Where in United States

  • Johns Hopkins University/Sidney Kimmel Cancer CenterBaltimore, United States

About the trial

What the trial wants to find out

The trial studies the effects of personalized home-based aerobic and resistance exercises on quality of life, changes in physical activity levels, and the change in inflammatory myokines with the exercise intervention in Interleukin 6 (IL-6), C-reactive Protein (CRP), Leptin, Transforming growth factor beta (TGF-beta), and Interferon (INF) gamma.

The group in the trial

  • Supportive CareTreatment being tested

    Patients with metastatic renal cell carcinoma (RCC) who are receiving immune-checkpoint inhibitor therapy

    Treatment: Combined Aerobic and Resistance Exercise Training

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study of Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
Record updated
4 April 2024